CN105377256A - 低剂量药物组合物 - Google Patents

低剂量药物组合物 Download PDF

Info

Publication number
CN105377256A
CN105377256A CN201480038832.0A CN201480038832A CN105377256A CN 105377256 A CN105377256 A CN 105377256A CN 201480038832 A CN201480038832 A CN 201480038832A CN 105377256 A CN105377256 A CN 105377256A
Authority
CN
China
Prior art keywords
deferasirox
pharmaceutical composition
dose pharmaceutical
low dose
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480038832.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·马尔霍特拉
S·M·普伦戴尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN105377256A publication Critical patent/CN105377256A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480038832.0A 2013-05-10 2014-05-08 低剂量药物组合物 Pending CN105377256A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1696/MUM/2013 2013-05-10
IN1696MU2013 IN2013MU01696A (2) 2013-05-10 2014-05-08
PCT/GB2014/051400 WO2014181108A1 (en) 2013-05-10 2014-05-08 Low dose pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN105377256A true CN105377256A (zh) 2016-03-02

Family

ID=50979804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480038832.0A Pending CN105377256A (zh) 2013-05-10 2014-05-08 低剂量药物组合物

Country Status (18)

Country Link
US (4) US20160120847A1 (2)
EP (1) EP2994131A1 (2)
JP (1) JP2016518398A (2)
CN (1) CN105377256A (2)
AP (1) AP2015008875A0 (2)
AU (1) AU2014264421A1 (2)
BR (1) BR112015028257A2 (2)
CA (1) CA2911671A1 (2)
EC (1) ECSP15051434A (2)
HK (1) HK1215191A1 (2)
IN (1) IN2013MU01696A (2)
MX (1) MX2015015553A (2)
PE (1) PE20151934A1 (2)
PH (1) PH12015502557A1 (2)
RU (1) RU2015149544A (2)
SG (1) SG11201509308TA (2)
WO (1) WO2014181108A1 (2)
ZA (1) ZA201403276B (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105853367A (zh) * 2016-05-10 2016-08-17 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
CN115154428A (zh) * 2022-09-06 2022-10-11 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088A (zh) * 2022-09-06 2022-11-29 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018517734A (ja) * 2015-06-17 2018-07-05 ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー デフェラシロクスの改善された製剤およびその作製方法
RU2616267C1 (ru) * 2016-01-25 2017-04-13 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения
WO2017158559A1 (en) * 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
JP7246384B2 (ja) * 2017-10-25 2023-03-27 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 遅延放出デフェリプロン錠剤及びその使用法
CN109646423A (zh) * 2018-12-03 2019-04-19 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049395A1 (en) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
WO2004035026A1 (en) * 2002-10-15 2004-04-29 Novartis Ag Deferacirox dispersible tablets
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2012042224A2 (en) * 2010-10-01 2012-04-05 Cipla Limited Pharmaceutical composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408078D0 (en) 2004-04-08 2004-05-12 Novartis Ag Organic compounds
NZ567155A (en) 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
EP2758436B1 (en) * 2011-09-23 2019-06-12 Universität Stuttgart Serum half-life extension using immunoglobulin binding domains

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049395A1 (en) * 1996-06-25 1997-12-31 Novartis-Erfindungen Verwaltungsgesellschaft M.B.H. Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
WO2004035026A1 (en) * 2002-10-15 2004-04-29 Novartis Ag Deferacirox dispersible tablets
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
WO2012042224A2 (en) * 2010-10-01 2012-04-05 Cipla Limited Pharmaceutical composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COHEN ET AL: "Effect of transfusional iron intake on response to chelayion therapy in beta thalassemia major", 《BLOOD》 *
GARADAH ET AL: "The impact of two different doses of chelating therapy(deferasirox) on echocardiographic tissue Doppler indices in patients with thalassemia major", 《EUROPEAN JOURNAL OF HAEMATOLOGY》 *
RENZO GALANELLO ET AL: "Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta thalassemia major", 《HAEMATOLOGICA》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105853367A (zh) * 2016-05-10 2016-08-17 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
CN105853367B (zh) * 2016-05-10 2019-07-12 广州加德恩医药有限公司 地拉罗司固体分散体的制备方法及其药物制剂
CN115154428A (zh) * 2022-09-06 2022-10-11 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088A (zh) * 2022-09-06 2022-11-29 上海奥科达生物医药科技有限公司 一种地拉罗司药物组合物及其制备方法
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN115400088B (zh) * 2022-09-06 2023-07-07 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Also Published As

Publication number Publication date
JP2016518398A (ja) 2016-06-23
US20170095453A1 (en) 2017-04-06
US20160120847A1 (en) 2016-05-05
EP2994131A1 (en) 2016-03-16
SG11201509308TA (en) 2015-12-30
US20170312254A1 (en) 2017-11-02
CA2911671A1 (en) 2014-11-13
US20160158202A1 (en) 2016-06-09
MX2015015553A (es) 2016-06-17
RU2015149544A (ru) 2017-06-16
ECSP15051434A (es) 2017-05-31
AU2014264421A1 (en) 2015-12-03
PE20151934A1 (es) 2015-12-26
BR112015028257A2 (pt) 2017-07-25
PH12015502557A1 (en) 2016-02-22
WO2014181108A1 (en) 2014-11-13
ZA201403276B (en) 2015-07-29
AP2015008875A0 (en) 2015-11-30
IN2013MU01696A (2) 2015-06-26
HK1215191A1 (zh) 2016-08-19

Similar Documents

Publication Publication Date Title
US20170312254A1 (en) Low Dose Pharmaceutical Composition
US20180311216A1 (en) Pharmaceutical Composition Comprising Deferasirox
WO2015071668A1 (en) Pharmaceutical compositions
JP2011516613A (ja) 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
JP2013189455A (ja) 弱塩基性薬および有機酸を含む薬物送達系
KR20130076818A (ko) 약학 조성물
KR20150084771A (ko) 데페라시록스 및 데페리프론를 포함하는 고정 투여량 약학 조성물
US20150104511A1 (en) Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine
EP3836920B1 (en) Formulations of ag10
CN103249415B (zh) 包含盐酸乐卡地平和缬沙坦的复合制剂及其制备方法
OA19858A (en) Low dose pharmaceutical composition.
KR20160016845A (ko) 저-투여량 약학 조성물
US12296050B2 (en) Pharmaceutical compositions comprising maralixibat and uses thereof
KR102936624B1 (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
EP2797583B1 (en) Combined pharmaceutical formulation containing diacerein
HK1214171B (en) Cenicriviroc compositions and methods of making and using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160302